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Abstract: Bimatoprost is the only representative of a novel class of prostaglandin ethanolamide 
(prostamide) compounds used therapeutically as an efficacious treatment for glaucoma. The 
pathways through which bimatoprost works to improve uveoscleral outflow to relieve elevated 
intraocular pressure are similar to those of the conventional prostaglandins used in glaucoma 
therapy, with some evidence of a preferential action at the trabecular meshwork. The pharma-
cology of bimatoprost is however, unclear. Pharmacological evidence supports a specific and 
distinct receptor-mediated agonist activity of bimatoprost at ‘prostamide’ receptors, which is 
selective to the prostamides as a class. However, other studies have reported either activity of 
bimatoprost at additional prostanoid and nonprostanoid receptors, or a conversion of bimatoprost 
to metabolites with agonist activity at prostaglandin FP receptors in the human eye. The forma-
tion of endogenous prostamides has been demonstrated in vivo, by a novel pathway involving 
the cyclooxygenase-2-mediated conversion of endogenous cannabinoid (endocannabinoid) sub-
strates. Irrespective of the pharmacology of bimatoprost and the prostamides in general, further 
studies are needed to determine the biological role and biochemical pathology of prostamides 
in the human eye, particularly in glaucoma. Such studies may improve our understanding of 
uveoscleral flow and may offer new treatments for controlling intraocular pressure.
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Glaucoma is a chronic disease of the optic nerve, caused at least in part by a sus-
tained, elevated intraocular pressure. Mechanisms of optic deterioration include 
direct axonal damage, structural failure, and altered microvascular supply.1 Intra-
ocular pressure is normally maintained at a steady state and in health eyes assumes 
a relatively narrow range. The intraocular pressure in any given eye is determined 
by the rate of fluid (aqueous) production within the eye by the ciliary body and the 
drainage of aqueous humor from the eye through the trabecular meshwork, aqueous 
flow, and uveoscleral outflow. In glaucomatous eyes, the increased resistance to 
aqueous humor outflow is due in part to an increase in extracellular matrix deposited 
in the trabecular meshwork, but also in other outflow structures such as Schlemm’s 
canal,2 with the amount of extracellular matrix correlated with the loss of axons 
in the optic nerve.3 One study found that inflammatory genes were upregulated in 
trabecular meshwork from primary open-angle glaucomatous eyes under conditions Clinical Ophthalmology 2009:3 664
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of explant culture, compared to nonglaucomatous eyes.4 
However, many genes in the trabecular meshwork under-
went altered expression under culture conditions, so the 
pathological relevance of these changes is unclear. While 
a host of other cellular and interstitial changes also occur 
in the outflow facility during glaucoma that lead to the loss 
of normal drainage via this tissue,5 the pathogenic factors 
underlying glaucoma are still uncertain. This is partly a 
consequence of the complex physiological determinants of 
resistance within the outflow facility.6 In addition, there are 
difficulties in mimicking primary angle open glaucoma in 
animal models, and the limited translational value of in vitro 
approaches such as whole organ, anterior segment and cell 
culture studies (such as studies in trabecular meshwork 
cells), ensures that the pathogenesis of glaucoma to date 
remains enigmatic.4,7
In order to decrease intraocular pressure, most glaucoma 
drug treatments alter either the rate of aqueous humor 
production (eg, beta blockers, carbonic anhydrase inhibitors) 
or the outflow pathway (eg, prostanoids).8 This review will 
limit itself to a focus on the pharmacology and biochemi-
cal pathways of prostanoid-based therapies, in particular 
the prototypical therapeutic prostaglandin ethanolamide, 
bimatoprost. Irrespective of the antiglaucoma drug class, 
many patients on intraocular pressure-lowering drugs experi-
ence limitations in either efficacy or compliance, or display 
adverse side effects with long term use.9 Some patients 
will continue to progress to blindness.10
Prostanoids, cannabinoids, 
and prostamide pharmacology 
in the eye
Many clinically useful intraocular pressure-lowering 
agents act at prostaglandin FP receptors, responsive to 
the endogenous prostaglandin, prostaglandin F2α (PGF2α). 
These include such drugs as latanoprost and travoprost. 
Prostanoids play an important role in the control of 
intraocular pressure, primarily by increasing uveoscleral 
outflow via remodeling of the ciliary body.11 Therapy with 
prostaglandin analogues has been shown to effectively lower 
intraocular pressure over the long term,12 is often superior 
to other glaucoma therapies and shows fewer side effects.13 
While the prostanoid-based treatments have been found to 
possess similar profiles of efficacy of surveyed drugs within 
this class,14 other studies have demonstrated that bimatoprost 
is more efficacious.15,16 While other prostaglandin analogues 
acting at TP, EP, and DP receptors have been investigated 
in animal models of raised intraocular pressure, none have 
advanced clinically so far.17
An increase in trabecular meshwork outflow with 
prostanoid therapy has also been reported.17 The shape and 
area of the intertrabecular spaces of the trabecular meshwork 
normally determines the rate of aqueous outflow through this 
tissue (and hence intraocular pressure). Traditionally, the size 
of the pores within the trabecular meshwork was thought 
to be influenced by the tone of the adjacent ciliary muscle 
(CM), a smooth muscle component of the ciliary body with 
tendinous connections to the trabecular meshwork. However, 
studies have shown that trabecular meshwork has in itself 
contractile properties similar to smooth muscle.18–20 It has 
been suggested that this allows the trabecular meshwork to 
actively change the intertrabecular spaces by an autoregula-
tory mechanism.21 It is believed that trabecular meshwork 
contraction decreases aqueous outflow, while relaxation 
increases outflow.20 The relative contribution of the mesh-
work component to the overall reduction in intraocular pres-
sure with prostanoid treatments is not known, although the 
weak FP receptor agonist docosanoid unoprostone has been 
demonstrated to have a preferential action on the trabecular 
meshwork,17 as is also suggested for bimatoprost.22 Unopro-
stone may affect outflow indirectly or directly via additional 
cellular mechanisms, including the alteration of ion channel 
activation in the trabecular meshwork.23,24
Within this class of prostanoid-based drugs is bima-
toprost, which is structurally and chemically similar to 
the PGF2α analogues used in the treatment of glaucoma 
(Figure 1a). However, replacement of the carboxylate moiety 
with an ethanolamide functional group appears to confer to 
bimatoprost a substantially different pharmacology from the 
other representative PGF2α agonists.25 It is the first drug of 
its chemical class, termed the prostaglandin ethanolamides 
(prostamides), to have a therapeutic application.
Bimatoprost has demonstrated efficacy comparable to 
other prostanoids in the reduction of intraocular pressure.25,26 
While bimatoprost elicits a similar and clinically significant 
increase in uveoscleral outflow and possibly an increase 
in trabecular outflow facility as for the prostaglandins,17,22 
whether the mechanism(s) of its intraocular pressure-
lowering action are distinctive from that of the prostaglandins 
is still not known with certainty. It has been suggested that 
bimatoprost acts solely at the trabecular meshwork to increase 
aqueous outflow.27 Certainly, long-term changes in vascular-
ization, inflammatory cell infiltrate, and trabecular meshwork 
morphology are noted both with prostaglandin agonists 
and bimatoprost.28,29 Bimatoprost therapy is also associated Clinical Ophthalmology 2009:3 665
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with similar changes to extracellular matrix markers as with 
conventional prostaglandin treatments,24 indicating that 
longer term structural changes follow a similar pathway 
to the prostaglandins. Studies comparing bimatoprost with 
latanoprost found that the greater efficacy of intraocular 
pressure reductions with bimatoprost was offset by a higher 
incidence of conjunctival hyperemia,15,30 although replacing 
existing latanoprost therapy with bimatoprost was associated 
with lower rates of hyperemia.31,32 The reasons for enhanced 
conjunctival hyperemia with bimatoprost therapy are not 
known, but it is believed that part of the effect of bimatoprost 
is manifest as vasodilatation occurring independently of 
inflammation, generated through endothelial-derived nitric 
oxide formation.33 Hyperemia with long term prostanoid use 
has been attributed, either wholly or in part, to the benzal-
konium preservative in topical prostanoid ophthalmologic 
preparations.34,35 However, this most likely does not account 
for the hyperemia associated with bimatoprost formulations, 
where the comparative benzalkonium concentrations are 
relatively low.
Other changes noted with prostanoid therapy generally 
include elongation and darkening of eyelashes, induced 
iris darkening, and periocular skin pigmentation, which are 
mostly similarly evidenced with bimatoprost treatment.36 
Topical ocular prostanoids evoke increased immune marker 
expression in the eye, which infers that the prostanoids can 
evoke a mild inflammatory reaction.37 This altered immune 
marker expression is a feature that was also shared with 
bimatoprost therapy.37
Bimatoprost is a stable chemical entity representative of 
the endogenous prostamides, which themselves are only rela-
tively recent discoveries. Evidence has demonstrated that a 
major pathway for the production of endogenous prostamides 
is via the conversion of endogenous cannabinoid molecules, 
such as anandamide, via the action of cyclooxygenase-2 
(COX-2)38 (Figure 1b). Prostamides were subsequently 
shown to be produced in vivo utilizing knock-out mice for 
the normal endocannabinoid metabolising enzyme, fatty acid 
amide hydrolase (FAAH).39 Another major endocannabinoid 
molecule, 2-arachidonoyl glycerol is also a substrate for 
COX-2, producing prostaglandin glycerol esters. A recent 
study also suggested other pathways for prostamide produc-
tion exist and are yet to be fully characterized.40 While the 
constitutive COX-1 does not display an affinity for the endo-
cannabinoids as an enzyme substrate, it is also recognized 
that the endocannabinoids are substrates for other oxidation 
pathways aside from COX-2, such as via lipoxygenases and 
cytochrome P450 enzymes.41
The prostamides have been shown to influence intraocular 
pressure in a similar fashion to conventional prostaglandin 
PGF2α agonists.42 However, they are believed to act at recep-
tors distinct from conventional prostaglandins, namely via a 
separate class of ‘prostamide’ receptors.26,43 Indeed, bimato-
prost is believed to act at distinct ‘prostamide’ receptors to 
mediate intraocular pressure reductions in glaucoma.43,44 The 
precise biological role of the prostamides compared to pros-
taglandins generally is not known, either in ocular physiology 
or in other systems.45 Certainly there appear to be functional 
pharmacological differences between the two prostanoid 
classes. Studies utilizing in vitro bioassays such as trabecular 
meshwork, ciliary and iridial muscle preparations, and cell 
culture expression systems ostensibly preclude a conventional 
FP receptor component to bimatoprost’s activity.25,44,46
The pharmacological selectivity of the endogenous 
prostamides has been well characterized. Prostamides 
D2, E2, and F2α are only weakly active at human prosta-
glandin DP, EP, FP, IP, or TP receptors.47 The distinctive 
pharmacology of the prostamides is supported by the recent 
development of prostamide-selective antagonists.48 These 
have been demonstrated to block contractile responses in 
feline iris to prostamides (including bimatoprost), but not 
the corresponding prostaglandins.48 Prostamide metabolites 
were generally not believed to be responsible for activity 
as assessed in vitro using either recombinant cell lines or 
functional bioassays.47 However, another in vitro study in 
human eye tissues showed that bimatoprost was rapidly 
hydrolyzed in cornea, iris, sclera, and ciliary muscle to its 
corresponding 17-phenyl-PGF2α metabolite, known to be 
active at FP receptors.49
Other studies that question the unique pharmacological 
selectivity of bimatoprost include one demonstrating an activ-
ity at cannabinoid receptors in ciliary muscle,50 which con-
trasts to another study that demonstrated a negligible activity 
of prostamides at cannabinoid receptors.42 Cannabinoid 
receptor agonists lower intraocular pressure,51 potentially 
via an increased outflow facility through an action at the 
trabecular meshwork.52 An action of the cannabinoid CB1 
receptor antagonist SR141716A at ‘prostamide-sensitive’ 
receptors should be excluded to possibly clarify these 
anomalous findings.
The contractile effect of bimatoprost was also partly 
attributed to an agonist activity at the FP receptor, as attested 
to by the sensitivity of bimatoprost’s actions to the FP 
receptor antagonist AL8810.50 More recently, prostaglandin 
FP receptor variants forming heterodimers in cell expres-
sion systems accounted for the selectivity of bimatoprost, Clinical Ophthalmology 2009:3 666
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Figure 1 A) Chemical structure of bimatoprost B) Pathway for the production of prostaglandin ethanolamides (prostamides) via COX-2 mediated conversion of the major 
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which was reversible with prostamide-selective antagonists 
such as AGN211335.53 The molecular identification of the 
prostamide receptor(s) remains elusive, but speculation of 
an FP receptor splice variant accounting for the pharmaco-
logical variation has been proposed.25 The selectivity based 
purely on pharmacological actions will continue to raise an 
ambiguity as to the mechanism of bimatoprost’s actions.
It should also be reiterated that the major endocannabinoid 
molecules act at cannabinoid receptors expressed in the 
human eye, mainly in the retina54 but also in the trabecular 
meshwork.55 Exogenous cannabinoids and endocannabinoids 
exert functional influences in the eye, including the modu-
lation of aqueous humor production and outflow. ∆9-THC, 
the active psychotropic component of Cannabis Sativa, has 
been shown to increase aqueous outflow.56 2-Arachidonoyl 
glycerol infusion in anterior eye segments increases aqueous 
humor outflow and alters actin deposition, possibly via an 
action at the trabecular meshwork.57 Anandamide infusion 
has also been shown to increase the aqueous humor outflow 
facility.58 That both endocannabinoid molecules and their 
COX-2 metabolites, the prostamides, can alter aqueous and 
uveoscleral outflow independently makes the contribution of 
their interaction to intraocular pressure difficult to discern 
in vivo. That both systems are expressed in the eye may be 
important in eye pathologies, such as glaucoma, where the 
expression of each system may be altered, with a subse-
quent modulation of both endocannabinoid and prostamide 
expression. The functional sequelae of such changes would 
be intriguing, but has yet to be extensively investigated.
Biochemical pathology in relation 
to prostamides
There are only a limited number of studies that have 
separately investigated the expression of the endocannabinoid 
system and COX-2 in glaucoma, either in animal models or 
in human glaucoma. None have yet attempted to directly 
measure prostamide levels in the eye at either normal or 
elevated intraocular pressure, so potential changes in pros-
tamide generation here are inferred from altered systems 
involved in their formation.
It is well established that COX-2 expression is inducible 
under inflammatory conditions; therefore it is attractive to 
consider that at the tissue level, marked changes in COX-2 
activity could dramatically alter the local fate of endocan-
nabinoids. Under such conditions, endocannabinoids may be 
diverted into the production or prostamides and prostaglandin 
glycerol esters, which may possess a diverse suite of biologi-
cal effects that are as yet to be defined.
Elements of both the tissue endocannabinoid system and 
COX-2 are expressed in the human eye, and perturbations in 
both endocannabinoid and COX-2 expression seem to follow 
similar patterns in human glaucoma. Endocannabinoids such 
as 2-AG are expressed in the human uveoscleral region in 
reduced levels in human glaucomatous eyes.59 While there is 
a degree of constitutive COX-2 expression in the human eye, 
COX-2 expression is significantly reduced in human primary 
open angle glaucoma.60 Thus, a possible scenario in glaucoma 
is one of a combination of both reduced COX-2 expres-
sion and reduced endocannabinoid substrates for COX-2, 
impinging upon a potentially important regulatory process 
for controlling aqueous outflow. The interaction between 
COX-2 and the cannabinoids is strengthened by evidence 
that methanandamide, a stable mimic of the endogenous 
cannabinoid anandamide, directly stimulates COX-2 
expression in human nonpigmented ciliary epithelial cells,61 
in addition to independently lowering intraocular pressure 
through an effect on outflow via conventional cannabinioid 
receptors. The induction of COX-2 in ciliary epithelial cells 
is a feature also shared by exposure to prostaglandins such 
as prostaglandin E2 (PGE2).62
In animal studies of the ocular endocannabinoid system, 
the focus has been on changes in retinal tissue markers as 
opposed to outflow structures. Nonetheless, as a result of 
acute elevations in intraocular pressure, rat retina shows 
enhanced fatty acid amide hydrolase (FAAH) expression 
and reduced anandamide levels, together with reduced 
cannabinoid CB1 receptor expression.63 Implications for 
retinal protection were discussed by Nucci and colleagues.63 
However, reduced expression or greater turnover of prosta-
mide substrates in outflow structures as a consequence of 
such changes in endocannabinoid markers could exacerbate 
intraocular pressure increases, by impinging on aqueous 
outflow.
Although ocular COX-2 expression is enhanced in animal 
models of glaucoma,64 focused studies on humans showing 
reduced expression of ocular COX-2 in primary open-angle 
glaucoma and steroid-induced glaucoma60 lend support to a 
more reliable clinical picture of changes in COX-2 versus 
animal models. Contrary to the view that COX-2 is proin-
flammatory, COX-2 expression may be reparative, producing 
enhanced levels of prostaglandins and prostamides in an 
effort to restore normal aqueous outflow in acute models of 
elevated intraocular pressure. The production of prostamides 
versus prostaglandins in this setting is also an interesting 
question, where COX-2 expression and activity is altered. 
Under conditions of cytokine incubation, explants and cell Clinical Ophthalmology 2009:3 668
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cultures can produce significant proportions of prostamides 
compared to prostaglandins.65 In some studies of glaucoma, 
where aqueous humor shows significantly reduced PGE2 
levels compared to control,60 there may be a differential 
reduction in prostamides or prostaglandin concentrations 
that cannot be distinguished using commercial prostaglandin 
immunoassays, due to the complete immune cross reactivity 
between the two classes of prostanoid.65 The implication 
of such a differential change occurring in the eye is not 
known, given that both prostamides and prostaglandins 
mediate increases in uveoscleral outflow and reductions in 
intraocular pressure. It is interesting to note that prostanoids 
such as latanoprost directly stimulate COX-2 production in 
human nonpigmented ciliary epithelial cells and that this 
is a requirement for matrix metalloproteinase expression.66 
Taken together with evidence that human aqueous humor 
shows significantly reduced PGE2 levels in glaucoma,60 
it is conceivable that prostanoids permit the restitution of 
ocular COX-2 expression, which in turn restores the normal 
structural and functional components of the outflow facility. 
As this feature is also shared with endocannabinoid ana-
logues, it will be important to determine if a similar property 
of the prostaglandins is shared with prostamide therapy.
Studies investigating the effects of long-term use of 
COX-2 inhibitors (‘coxibs’) with intraocular pressure 
changes would also be of interest, especially given the 
reports of ocular side effects associated with their use.67 
Nonselective, nonsteroidal anti-inflammatory drugs are 
used in a variety of ophthalmologic conditions, and coxibs 
have a demonstrated development potential as new treat-
ments for corneal angiogenesis and diabetic retinopathy.68 
Interestingly, administration of the COX-2 selective inhibitor 
nimesulide was found to enhance the intraocular pressure-
lowering effect of latanoprost in patients with primary 
open-angle glaucoma.69 This likely suggests that the overall 
COX-2 mediated production of a suite of prostanoids, with 
sometimes contrasting effects, needs to be considered, 
rather than just focusing on the role of prostamides in the 
control of intraocular pressure. Monitoring of intraocular 
pressure may, in any event, be warranted where COX-2 
inhibitors are to be used topically in such settings over an 
extended period.
The role of endocannabinoid system in glaucoma may 
thus be of importance, not only because of the direct positive 
effects on outflow of the endocannabinoid molecules, but 
also for the provision of substrates for prostamide produc-
tion, in addition to a potential neuroprotective contribution 
to the optic nerve.70 The reduced endocannabinoid levels 
demonstrated in outflow pathways in human glaucomatous 
eyes59 may exert a marked effect on outflow, both directly 
through reduced cannabinoid-induced outflow and indirectly, 
via reduced prostamide production. Irrespective of the final 
mediator (endocannabinoid or prostamide), there is a poten-
tial to investigate the inhibition of endogenous cannabinoid 
metabolism as a potential antiglaucoma therapy. Anandamide 
and 2-AG are broken down by the FAAH enzyme. Inhibitors 
of FAAH or FAAH gene knockouts increase tissue endo-
cannabinoid concentrations,39 including in the trabecular 
meshwork of the eye.57 Studies will firstly need to directly 
measure the formation of prostamides to verify their place 
in the control of intraocular pressure and altered expression 
in the setting of glaucoma.
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